Lupin gets USFDA approval for hypertension drug

The approval is to market generic version of Diovan HCT Tablets, a hypertension drug, in the US.

 

New Delhi, March 22, 2013: The Indian drug major Lupin today said that the company has received the approval from the US health drug regulator for marketing the generic version of Novartis Pharmaceuticals Corp's Diovan HCT Tablets, a hypertension drug, in the US.

 

Lupin Pharmaceuticals Inc, a subsidiary of Lupin has received the approval from US Food and Drug Administration (USFDA) for its Valsartan and Hydrochlorothiazide Tablets (HCT).


 

The company also said that it has already started shipping the product to the US market. Going by the IMS data for the month of September 2012, Valsartan and Hydrochlorothiazide Tablets had sales of around US$ 1.7 billion in the US market and thus represent a huge opportunity for Lupin.

Comment!
 
 






* Indicates mandatory field.
Please wait while comments are being sent...